CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas., Jiang, Yanwen, Ortega-Molina Ana, Geng Huimin, Ying Hsia-Yuan, Hatzi Katerina, Parsa Sara, McNally Dylan, Wang Ling, Doane Ashley S., Agirre Xabier, et al. , Cancer Discov, 2017 Jan, Volume 7, Issue 1, p.38-53, (2017)

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma., Cardenas, Mariano G., Yu Wenbo, Béguelin Wendy, Teater Matthew R., Geng Huimin, Goldstein Rebecca L., Oswald Erin, Hatzi Katerina, Yang Shao-Ning, Cohen Joanna, et al. , J Clin Invest, 2016 Sep 01, Volume 126, Issue 9, p.3351-62, (2016)

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma., Goldstein, Rebecca L., Yang Shao Ning, Taldone Tony, Chang Betty, Gerecitano John, Elenitoba-Johnson Kojo, Shaknovich Rita, Tam Wayne, Leonard John P., Chiosis Gabriela, et al. , J Clin Invest, 2015 Nov 03, Volume 125, Issue 12, p.4559-71, (2015)

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma., Clozel, Thomas, Yang ShaoNing, Elstrom Rebecca L., Tam Wayne, Martin Peter, Kormaksson Matthias, Banerjee Samprit, Vasanthakumar Aparna, Culjkovic Biljana, Scott David W., et al. , Cancer Discov, 2013 Sep, Volume 3, Issue 9, p.1002-19, (2013)

The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma., Oricchio, Elisa, Nanjangud Gouri, Wolfe Andrew L., Schatz Jonathan H., Mavrakis Konstantinos J., Jiang Man, Liu Xiaoping, Bruno Joanne, Heguy Adriana, Olshen Adam B., et al. , Cell, 2011 Oct 28, Volume 147, Issue 3, p.554-64, (2011)